瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06938 瑞博生物-B

国庆日休市 09-30 16:08:27

56.950

+2.600

+4.78%

最高57.650	最低54.950	成交量28.16万
今开55.150	昨收54.350	日振幅4.97%
总市值96.82亿	流通市值96.82亿	总股本1.70亿
成交额1,600万	换手率0.17%	流通股本1.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":56.95,"timestamp":1790755707008,"preClose":54.35,"halted":0,"volume":281600,"delay":0,"changeRate":0.04783808647654096,"floatShares":170000000,"shares":170000000,"eps":-2.100221,"marketStatus":"国庆日休市","change":2.6,"latestTime":"09-30 16:08:27","open":55.15,"high":57.65,"low":54.95,"amount":16003962,"amplitude":0.049678,"askPrice":57,"askSize":90000,"bidPrice":56.95,"bidSize":800,"shortable":3,"etf":0,"ttmEps":-1.149,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790904600000},"marketStatusCode":7,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":54.35,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"volumeRatio":1.5256257458436386,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06938","defaultTab":"news","newsList":[{"id":"2671267715","title":"瑞博生物-B午前涨逾5% 公司自动化智能药物筛选中心落成","url":"https://stock-news.laohu8.com/highlight/detail?id=2671267715","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671267715?lang=zh_cn&edition=full","pubTime":"2026-09-29 11:30","pubTimestamp":1790652600,"startTime":"0","endTime":"0","summary":"模拟交易客户端瑞博生物-B午前涨逾5%，截至发稿，股价上涨4.88%，现报53.65港元，成交额358.05万港元。近日，据瑞博生物官微消息，公司宣布，旗下全资子公司瑞博泰克（山东）生物医药科技有限公司自动化智能药物筛选中心正式落成。瑞博生物正迎来管线成果加速释放阶段：自研肝靶向技术持续成熟，肝外递送技术获得重要突破。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-29/doc-initnfqm3016755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06938","PBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671621822","title":"港股异动 | 瑞博生物-B(06938.HK)涨超5% 自动化智能药物筛选中心落成 公司迎管线成果加速释放阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2671621822","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671621822?lang=zh_cn&edition=full","pubTime":"2026-09-29 10:35","pubTimestamp":1790649323,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669093891","title":"港股全日表现疲软 恒指收跌1.01% OpenClaw概念股受挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2669093891","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669093891?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:26","pubTimestamp":1790151963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股全日表现疲软，午后跌幅进一步扩大，三大股指均跌逾1%，截至收盘，恒生指数报24834.12点，下跌1.01%；国企指数下跌1.06%；恒生科技指数下跌1.33%。个股方面，老铺黄金盘中股价持续受压下挫，全天收跌2.70%。总结下半年，该行预计老铺黄金收入料介于75亿至105亿元人民币，同比下跌15%至39%，净利润介于12.6亿至20.1亿元人民币，净利润率16.8%至19.2%。招商证券国际发报告指，瑞博生物2026年上半年实现收入4.2亿元，超市场预期，截至中报在手现金22亿元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992341","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","MCHmain","06938","07300","HHImain","513600","06181","02800","SG9999001051.SGD","07500","SGXZ90724238.SGD","BK1227","03419","HSI","83115","09115","03115","02833","BK1544","07200","HSTECH","82800","03037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669717746","title":"瑞博生物-B（06938）午后涨3.36% 机构指其纳入港股通 基本面和资金面多维度提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2669717746","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669717746?lang=zh_cn&edition=full","pubTime":"2026-09-23 13:22","pubTimestamp":1790140964,"startTime":"0","endTime":"0","summary":"金吾财讯 | 瑞博生物-B（06938）股价反复扬升，午后升幅微扩，最新报56.85港元，涨3.36%，成交额468.35万港元。招商证券国际发报告指，瑞博生物2026年上半年实现收入4.2亿元，超市场预期，截至中报在手现金22亿元。RBD4059针对心房颤动和VTE的临床2b稳步推进，预计将进行4个2b期临床。另外，公司纳入港股通，基本面和资金面多维度提升。基于临床II期以上开发阶段的4款资产（3款拥有全球权益+1款国内权益授权给齐鲁），该行预计公司2026-2028年营业收入分别为4.4/1.2/1.5亿元人民币。维持瑞博生物目标价105港元以及“增持”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992325","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLHK","06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157825605","title":"瑞博生物-B2026年中期财报：营收4.20亿元，同比增长304.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157825605","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157825605?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:37","pubTimestamp":1789979854,"startTime":"0","endTime":"0","summary":"本季度信息\n瑞博生物-B（06938）发布的2026年中期财报显示，报告期内实现营收4.20亿元，同比增长304.3%。毛利4.01亿元，同比增幅达312.2%。经营活动所产生的现金流量净额从上年同期的-0.96亿元转为2.13亿元，呈现明显改善。\n报告期内公司加大了研发投入，研发费用约为1.98亿元，较上年同期的1.29亿元增长53.0%，研发投入占营收比约为47.14%。销售及分销开支同比下降14.5%，管理层指出主要由于营销推广费用减少所致；行政开支则同比增加20.9%，主要由与上市相关的专业及咨询服务费提升所带动。\n","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"瑞博生物-B2026年中期财报：营收4.20亿元，同比增长304.3%","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154234281","title":"瑞博生物-B：9月16日回购18.16万股，耗资约933.16万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154234281","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154234281?lang=zh_cn&edition=full","pubTime":"2026-09-16 20:02","pubTimestamp":1789560161,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年9月16日发布翌日披露报表，披露当日于香港联交所场内回购H股股份。根据公告，本次回购数量为181,600股，占当日前已发行股本约0.107%，最高回购价为每股港币52元，最低回购价为每股港币49.96元，合计耗资约9,331,640港元。此前，公司于2026年6月5日获股东大会通过股份回购授权，总计可回购17,055,491股。公司表示，本次回购严格遵守香港联交所上市规则及有关法律法规。本公告由联席公司秘书张甦签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：9月16日回购18.16万股，耗资约933.16万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667988108","title":"瑞博生物-B(06938.HK)9月16日斥资约933.16万港元回购18.16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667988108","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667988108?lang=zh_cn&edition=full","pubTime":"2026-09-16 20:00","pubTimestamp":1789560026,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186497229","title":"瑞博生物-B：9月11日回购171,800股，耗资约934.78万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186497229","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186497229?lang=zh_cn&edition=full","pubTime":"2026-09-11 21:42","pubTimestamp":1789134177,"startTime":"0","endTime":"0","summary":"2026年9月11日，苏州瑞博生物技术股份有限公司发布公告，披露于同日于香港联交所场内回购股份171,800股，占该公司此前已发行股份总数的0.1011%。本次回购每股价格介乎53.20港元至55.70港元，合计耗资约9,347,770港元。公司回购授权于2026年6月5日获股东大会通过，授权回购股份总数为17,055,491股，截至目前已在香港联交所或其他证券交易所累计回购790,400股，占授权当日已发行股份总数的0.4634%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：9月11日回购171,800股，耗资约934.78万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666552717","title":"瑞博生物-B(06938.HK)9月11日斥资934.8万港元回购17.18万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666552717","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666552717?lang=zh_cn&edition=full","pubTime":"2026-09-11 21:32","pubTimestamp":1789133540,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169606176","title":"瑞博生物-B：9月9日回购3.26万股，耗资约188.27万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169606176","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169606176?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:15","pubTimestamp":1788952552,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年9月9日发布翌日披露报表，公告显示公司于当日回购了32,600股H股普通股，占回购前已发行股份总数的约0.0192%。本次回购于香港联交所场内进行，回购价格为每股57.75港元，合计耗资1,882,650港元，折合约188.27万港元。公司回购授权于2026年6月5日获得股东大会批准，授权可回购股份总数为17,055,491股。公司在报告中强调，已遵守香港联合交易所证券上市规则与相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：9月9日回购3.26万股，耗资约188.27万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134573401","title":"瑞博生物-B：9月8日回购1.66万股，耗资约95.87万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134573401","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134573401?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:45","pubTimestamp":1788867955,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年9月8日发布翌日披露报表。公司于当日通过香港联交所场内回购股份1.66万股，占回购前已发行股本的约0.0098%。本次回购每股价格为57.75港元，总耗资约95.87万港元。回购后，公司已发行股本由169,985,510股减少至169,968,910股，同时库藏股数增加至586,000股，总股本维持在170,554,910股。本次回购已获得公司董事会授权，并符合相关上市规则及法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：9月8日回购1.66万股，耗资约95.87万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665272123","title":"瑞博生物-B(06938)9月8日斥资95.87万港元回购1.66万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665272123","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665272123?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:44","pubTimestamp":1788867853,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年9月8日斥资95.87万港元回购1.66万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665941513","title":"招商证券国际：维持瑞博生物(06938.HK)“增持”评级 目标价105港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665941513","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665941513?lang=zh_cn&edition=full","pubTime":"2026-09-07 13:40","pubTimestamp":1788759653,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06099","BK1564","06938","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665996933","title":"瑞博生物-B(06938.HK)获纳入恒生综合指数成份股及获调入港股通股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2665996933","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665996933?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:30","pubTimestamp":1788755409,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665944399","title":"双重纳入落地：瑞博生物获纳入恒生综合指数、沪港通及深港通标的证券","url":"https://stock-news.laohu8.com/highlight/detail?id=2665944399","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665944399?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:25","pubTimestamp":1788755100,"startTime":"0","endTime":"0","summary":"瑞博生物（06938）发布公告，宣布其股份已被纳入恒生综合指数成份股，同时也被纳入沪港通及深港通南向交易的标的证券名单，自2026年9月7日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866531735.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866531735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06938","HSCI","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108696273","title":"瑞博生物-B（06938）将于2026年9月7日纳入恒生综合指数及港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=1108696273","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108696273?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:16","pubTimestamp":1788754560,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司（06938，瑞博生物-B）9月7日发布自愿公告称，根据恒生指数有限公司公告，公司股份已被纳入恒生综合指数成份股，并同步调入沪港通及深港通南向交易的港股通证券名单，生效日期同为2026年9月7日。\n公司表示，进入恒生综合指数及港股通标的范围，标志着其在资本市场发展历程中的重要节点，有助于提升股份流动性、拓宽投资者基础并优化股东结构。\n截至公告日期，公司董事会成员包括执行董事梁子才博士、甘黎明博士及张鸿雁博士；非执行董事戚飞博士、李东方先生及李宇辉先生；独立非执行董事宇学峰博士、马朝松先生及王瑞平先生。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119054073","title":"瑞博生物-B更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1119054073","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119054073?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:15","pubTimestamp":1788516947,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年9月4日发布截至2026年8月31日止的股份变动月报表。根据公告，瑞博生物-B本月法定注册股本维持在人民币170,554,910元，未发生增减变动。本月未进行任何新发行、购回或注销股份活动，公司满足相关公众持股量要求。在期权与股权激励方面，瑞博生物-B当前有上市前股份期权计划2,113,987份，行使价格为每股人民币3.70元，最早归属日期为2028年1月9日。上述公告由联席公司秘书张甦于2026年9月4日签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664823893","title":"瑞博生物-B早盘涨逾4% 中期净利润为0.23亿元同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2664823893","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664823893?lang=zh_cn&edition=full","pubTime":"2026-09-02 11:05","pubTimestamp":1788318300,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端瑞博生物-B（06938）盘中涨近5%，截至发稿，股价上涨3.73%，现报62.60港元，成交额1107.78万港元。近日，瑞博生物-B披露2026年中期业绩，公司实现收入人民币4.2亿元，同比增长304%；期内净利润为人民币0.23亿元，同比实现扭亏为盈，期末现金及现金等价物为人民币22.4亿元。业绩改善主要得益于全球合作项目相关许可收入的确认及合作里程碑的持续推进。与此同时，公司继续保持对核心临床管线及创新递送平台的研发投入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-02/doc-iniqkzma1367838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664987058","title":"港股异动 | 瑞博生物-B(06938.HK)涨近5% 中期业绩实现盈利且持续改善 肝外技术有望引领下一代蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2664987058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664987058?lang=zh_cn&edition=full","pubTime":"2026-09-02 10:51","pubTimestamp":1788317460,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664860319","title":"中金：维持瑞博生物-B(06938.HK)跑赢行业评级 目标价90港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664860319","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664860319?lang=zh_cn&edition=full","pubTime":"2026-09-02 09:12","pubTimestamp":1788311552,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ribolia.com","stockEarnings":[{"period":"1week","weight":0.0261},{"period":"1month","weight":-0.0548},{"period":"3month","weight":0.139},{"period":"6month","weight":-0.1198},{"period":"1year","weight":-0.0176},{"period":"ytd","weight":-0.0176}],"compareEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":-0.0373},{"period":"3month","weight":0.0676},{"period":"6month","weight":-0.02},{"period":"1year","weight":-0.0835},{"period":"ytd","weight":-0.0397}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州瑞博生物技术股份有限公司是一家主要从事小核酸药物研究和开发，尤其专注于小干扰核酸（siRNA）疗法的中国公司。该公司主要从事小核酸药物的创新，专注于心血管、代谢类、肾脏和肝病以及其他治疗领域。该公司的药物管线包括RBD4059、RBD5044、RBD7022、RBD7007、RBD2080、RBD1119、RBD1016等。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"瑞博生物-B","nameEN":"RIBOLIFE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞博生物-B,06938,瑞博生物-B股票,瑞博生物-B股票老虎,瑞博生物-B股票老虎国际,瑞博生物-B行情,瑞博生物-B股票行情,瑞博生物-B股价,瑞博生物-B股市,瑞博生物-B股票价格,瑞博生物-B股票交易,瑞博生物-B股票购买,瑞博生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}